"Examining the Hemocompatibility Effects of Aspirin on LVAD Patients with Advanced Heart Failure"
A randomized trial called ARIES-HM3 found that avoiding aspirin as part of an antithrombotic regimen, which includes a vitamin K antagonist, in patients with advanced heart failure supported by a fully magnetically levitated left ventricular assist device (LVAD) resulted in a significant decrease (34%) in major nonsurgical bleeding events without a significant increase in thromboembolic risk. The benefits of avoiding aspirin were consistent among patients with prior vascular disease and other risk factors associated with increased thrombosis risk. This study suggests that aspirin is not necessary for maintaining outcomes with a fully magnetically levitated LVAD and excluding it from the antithrombotic therapy can reduce bleeding events.